Amfetamina + deksamfetamina: interakcje

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Excessive Use of Arformoterol Tartrate Inhalation Solution and Use with Other Long-Acting Beta2-Agonists Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etykieta leku Arformoterol, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etykieta leku Budezonid + formoterol, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (etykieta leku Dronabinol, Ostrzeżenia i środki ostrożności)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

…life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as MAOIs, selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etykieta leku Flutykazon + salmeterol, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etykieta leku Formoterol, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

DO NOT EXCEED RECOMMENDED DOSE Fatalities have been reported in association with excessive use of inhaled products containing sympathomimetic amines and with the home use of nebulizers. (etykieta leku Ipratropium + salbutamol, Ostrzeżenia)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (etykieta leku Kokaina, Ostrzeżenie w ramce)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (etykieta leku Lewosalbutamol, Ostrzeżenia i środki ostrożności)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etykieta leku Lewotyroksyna + liotyronina, Ostrzeżenie w ramce)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (etykieta leku Liotyronina, Ostrzeżenie w ramce)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials ( 14 )]. (etykieta leku Oksybat sodu, Ostrzeżenie w ramce)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have been withdrawn from these drugs to determine whether or not the drugs, rather than Tourette’s Disorder, are responsible for the tics. (etykieta leku Pimozyd, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (etykieta leku Salbutamol, Ostrzeżenia i środki ostrożności)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etykieta leku Salmeterol, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

If serotonin syndrome occurs, discontinue ADDERALL XR and the CYP2D6 inhibitor [see Warnings and Precautions ( 5.8 ), Overdosage ( 10 )] . (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (etykieta leku Terbutalina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (etykieta leku Amfetamina + deksamfetamina, Przeciwwskazania)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (etykieta leku Umeklidynium + wilanterol, Ostrzeżenia i środki ostrożności)

Discontinue treatment with ADDERALL XR and any concomitant serotonergic agents immediately if symptoms of serotonin syndrome occur, and initiate supportive symptomatic treatment. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

• Risk of serotonin syndrome with concomitant therapy with other serotonergic drugs such as SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, and St. (etykieta leku Zyprazydon, Interakcje z innymi lekami)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (etykieta leku Acetazolamid, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (etykieta leku Aklidynium, Interakcje z innymi lekami)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (etykieta leku Alogliptyna + metformina, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Alprazolam, Ostrzeżenia i środki ostrożności)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (etykieta leku Bortezomib, Ostrzeżenia i środki ostrożności)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Chlordiazepoksyd, Ostrzeżenia)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Chlordiazepoksyd + klidynium, Ostrzeżenia)

Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max ) of amphetamine is decreased compared to when administered alone. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Diazepam, Ostrzeżenia)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (etykieta leku Dicykloweryna, Interakcje z innymi lekami)

Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (etykieta leku Digoksyna, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (etykieta leku Doksapram, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Sympathomimetic drugs: Dose adjustment needed (7) (etykieta leku Esmolol, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Estazolam, Ostrzeżenia)

Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max ) of amphetamine is decreased compared to when administered alone. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (etykieta leku Glimepiryd, Interakcje z innymi lekami)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (etykieta leku Glipizyd, Interakcje z innymi lekami)

In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine. (etykieta leku Guanfacyna, Ostrzeżenia i środki ostrożności)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etykieta leku Insulina aspart, Interakcje z innymi lekami)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etykieta leku Insulina degludec, Interakcje z innymi lekami)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etykieta leku Insulina detemir, Interakcje z innymi lekami)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etykieta leku Insulina glargine, Interakcje z innymi lekami)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etykieta leku Insulina lispro, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (etykieta leku Ketamina, Ostrzeżenia i środki ostrożności)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Klonazepam, Ostrzeżenia)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Klorazepan, Ostrzeżenia)

Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max ) of amphetamine is decreased compared to when administered alone. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Sympathomimetics Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. (etykieta leku Lewotyroksyna, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Lorazepam, Ostrzeżenia i środki ostrożności)

Sympathomimetics Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. (etykieta leku Metolazon, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max ) of amphetamine is decreased compared to when administered alone. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (etykieta leku Nateglinid, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Oksazepam, Ostrzeżenia)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max ) of amphetamine is decreased compared to when administered alone. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max ) of amphetamine is decreased compared to when administered alone. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (etykieta leku Pioglitazon + glimepiryd, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Proton Pump Inhibitors Clinical Impact Time to maximum concentration (T max ) of amphetamine is decreased compared to when administered alone. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (etykieta leku Sotalol, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Temazepam, Ostrzeżenia)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (etykieta leku Tiotropium, Interakcje z innymi lekami)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (etykieta leku Tolkapon, Interakcje z innymi lekami)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (etykieta leku Triazolam, Ostrzeżenia i środki ostrożności)

Tricyclic Antidepressants Clinical Impact May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etykieta leku Amfetamina + deksamfetamina, Ostrzeżenia i środki ostrożności)

Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (etykieta leku Acebutolol, Ostrzeżenia)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (etykieta leku Akarboza, Interakcje z innymi lekami)

Drug Interactions Careful observation is required when amantadine hydrochloride is administered concurrently with central nervous system stimulants. (etykieta leku Amantadyna, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (etykieta leku Bromokryptyna, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etykieta leku Dapagliflozyna + metformina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etykieta leku Empagliflozyna + metformina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etykieta leku Glibenklamid, Interakcje z innymi lekami)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etykieta leku Glibenklamid + metformina, Interakcje z innymi lekami)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etykieta leku Glipizyd + metformina, Środki ostrożności)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Atypical Antipsychotics (e.g., olanzapine and clozapine), Corticosteroids, Danazol, Diuretics, Estrogens, Glucagon, Isoniazid, Niacin, Oral Contraceptives, Phenothiazines, Progestogens (e.g., in oral contraceptives), Protease inhibitors, Somatropin, Sympathomimetic Agents (e.g., albuterol, epinephrine, terbutaline) and Thyroid Hormones. (etykieta leku Insulina ludzka krótko działająca, Interakcje z innymi lekami)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (etykieta leku Ipratropium, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods. (etykieta leku Labetalol, Interakcje z innymi lekami)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etykieta leku Linagliptyna + metformina, Interakcje z innymi lekami)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etykieta leku Metformina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etykieta leku Pioglitazon + metformina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (etykieta leku Ramelteon, Ostrzeżenia i środki ostrożności)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (etykieta leku Repaglinid, Interakcje z innymi lekami)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (etykieta leku Saksagliptyna + metformina, Interakcje z innymi lekami)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (etykieta leku Sytagliptyna + metformina, Interakcje z innymi lekami)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (etykieta leku Tiagabina, Ostrzeżenia)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (etykieta leku Amfetamina + deksamfetamina, Interakcje z innymi lekami)